Cumberland Pharmaceuticals (CPIX) Fundamental Analysis: Revenue, Earnings & Valuation

3.51 / 10

Netural

Cumberland Pharmaceuticals shows a fundamental score of 3.5/10, indicating weak standing. Key concerns include a high Days sales outstanding of 96.87 days, which suggests slow receivable collection, and a negative Cash-MV of -2.59, hinting at cash-flow challenges. While the Interest coverage ratio (15.48%) is adequate, the overall fundamental picture is constrained, warranting caution from an investment perspective.

Analysis Checks(8/10)

Revenue-MV

Value-0.21

Score2/3

Weight14.39%

1M Return7.73%

Total operating revenue (YoY growth rate %)

Value12.43

Score2/3

Weight1.57%

1M Return1.11%

Days sales outstanding

Value96.87

Score1/3

Weight-2.02%

1M Return-1.57%

Profit-MV

Value0.46

Score2/3

Weight14.66%

1M Return8.45%

Net income-Revenue

Value-0.17

Score2/3

Weight14.67%

1M Return8.45%

PB-ROE

Value-0.34

Score1/3

Weight17.85%

1M Return9.57%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.48

Score2/3

Weight-1.47%

1M Return-1.11%

Operating revenue (YoY growth rate %)

Value12.43

Score2/3

Weight0.60%

1M Return0.43%

Asset-MV

Value-0.50

Score2/3

Weight18.90%

1M Return10.15%

Cash-MV

Value-2.59

Score3/3

Weight20.85%

1M Return9.67%

Is CPIX fundamentally strong?

CPIX scores 3.51/10 on fundamentals and holds a Fair valuation at present. Backed by its -5.89% ROE, -8.09% net margin, -17.57 P/E ratio, 2.27 P/B ratio, and 68.47% earnings growth, these metrics solidify its Netural investment rating.